Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
US-9670236-B2 · Jun 6, 2017 · US
Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
US10233201B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10233201-B2 |
| Application number | US-201715607826-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 30, 2017 |
| Priority date | Oct 31, 2012 |
| Publication date | Mar 19, 2019 |
| Grant date | Mar 19, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds and compositions are provided that inhibit histone deacylase activity and which expand renal progenitor cell populations and improve kidney function in a damaged kidney. Methods of use of the compounds and compositions are provided.
First claim
Opening claim text (preview).
We claim: 1. A method of treating kidney injury in a patient, improving kidney function in a patient, stimulating kidney repair in a patient, inhibiting histone deacetylase in a cell, and/or expanding renal progenitor cells, comprising administering to a patient an amount of a compound having the formula: or a pharmaceutically acceptable salt thereof, effective to treat kidney injury or to improve kidney function in a patient. 2. The method of claim 1 , wherein the compound or pharmaceutically acceptable salt thereof is administered in an amount and in a dosage regimen effective to treating kidney injury in a patient, improving kidney function in a patient, stimulating kidney repair in a patient, inhibiting histone deacetylase in a cell, and/or expanding renal progenitor cells in vitro, ex vivo or in vivo.
Assignees
Inventors
Classifications
having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton · CPC title
having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton · CPC title
with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms · CPC title
Esters of aromatic acids (P-C aromatic linkage) · CPC title
Aromatic phosphine oxides or thioxides (P-C aromatic linkage) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10233201B2 cover?
- Compounds and compositions are provided that inhibit histone deacylase activity and which expand renal progenitor cell populations and improve kidney function in a damaged kidney. Methods of use of the compounds and compositions are provided.
- Who is the assignee on this patent?
- Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education, Univ Of Pittsburg—Of The Commonwealth System Of Higher Education
- What technology area does this patent fall under?
- Primary CPC classification C07C317/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).